many7's, I, too, am impressed w/ the Managements present ability to formulate this new side of DnaPrint Genomics. When one considers the "testing" company it used to be six years ago to the present, with the constant pressure of financial need to "split it's pennies" in an effort to procure the "acknowledgable staff" it has now, along w/ the growing acceptance w/in the medical community as referenced by the affiliations of Moffitt, Harvard, etc., then, with an open mind one can conclude that this Company, with it's immense talent will one day prosper and be accredited w/ "The Gold Standard" it has sought all along.
I am of the opinion that this latest buying spree is of "Long" investors who will hold their shares for the subsequent "obscene profits" to be had from DnaPrints Pipeline.
I have seen the share price run "three fold" in a few days, then retract due to lack of progress reporting from the company. I do not think management will allow this to happen again.
This company has credible science and is poised to utilize it's unique computational plateform that can accelerate the "trials" by correctly assesing thru Bayesian Theory a Theranostic approach to treatment vs metabolic toxicity.
News 
Market Data 
Discover 
